Canaccord Genuity Maintains Buy on BridgeBio Oncology, Lowers Price Target to $20

Benzinga · 1d ago
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $20.